During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

All slides were evaluated by a trained pathologist blinded to the patients’ clinical data. To deconvolute the cancer cell and immune cell components of the CPS, the slides were rescored by a trained ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

The following is a summary of “FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 ...

especially if the cancer can’t be removed with surgery. PD-1 is a checkpoint protein on immune cells called T cells. When PD-1 attaches to PD-L1, a protein on other cells in the body, it acts as a ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

Correspondence to Dr Ronan J Kelly, The Gastroesophageal Cancer Therapeutics Program, The Sidney Kimmel Comprehensive ... adenocarcinomas for their expression of programmed death-ligand 1 (PD-L1), ...

NICE says these patients taking Opdivo who had more PD-L1 (levels of 10% or more) on their cancer cells lived up to seven months longer than those with less. The committee have asked Bristol ...

This is a very large market opportunity and the company is starting off to target Non-Small Cell Lung Cancer patients who are PD-L1 positive. Plus, those who have metastatic disease. This is still ...